PL363245A1 - Compounds specific to adenosine a1 - Google Patents

Compounds specific to adenosine a1

Info

Publication number: PL363245A1
Authority: PL; Poland
Prior art keywords: adenosine; compounds specific; compounds; specific
Prior art date: 2000-12-01

Application number

PL01363245A

Other languages

Polish (pl)

Inventor

Arlindo L. Castelhano

Bryan Mckibben

David J. Witter

Original Assignee

Osi Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-01

Filing date

2001-11-30

Publication date

2004-11-15

2000-12-01 Priority claimed from US09/728,616 external-priority patent/US7160890B2/en

2000-12-01 Priority claimed from US09/728,316 external-priority patent/US6680322B2/en

2000-12-01 Priority claimed from US09/728,607 external-priority patent/US6664252B2/en

2001-11-30 Application filed by Osi Pharmaceuticals, Inc. filed Critical Osi Pharmaceuticals, Inc.

2004-11-15 Publication of PL363245A1 publication Critical patent/PL363245A1/en

Links

OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
239000002126 C01EB10 - Adenosine Substances 0.000 title 1
229960005305 adenosine Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Anesthesiology (AREA)
Otolaryngology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL01363245A 2000-12-01 2001-11-30 Compounds specific to adenosine a1 PL363245A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US09/728,616 US7160890B2 (en)	1999-12-02	2000-12-01	Compounds specific to adenosine A3 receptor and uses thereof
US09/728,316 US6680322B2 (en)	1999-12-02	2000-12-01	Compounds specific to adenosine A1 receptors and uses thereof
US09/728,607 US6664252B2 (en)	1999-12-02	2000-12-01	4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
PCT/US2001/045280 WO2002057267A1 (en)	2000-12-01	2001-11-30	Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof

Publications (1)

Publication Number	Publication Date
PL363245A1 true PL363245A1 (en)	2004-11-15

Family

ID=27419112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL01363245A PL363245A1 (en)	2000-12-01	2001-11-30	Compounds specific to adenosine a1

Country Status (20)

Country	Link
EP (1)	EP1347980A4 (en)
JP (1)	JP4579497B2 (en)
CN (1)	CN1263757C (en)
AP (1)	AP1893A (en)
AU (1)	AU2002248151B2 (en)
BR (1)	BR0115847A (en)
CA (1)	CA2430577A1 (en)
CZ (1)	CZ20031831A3 (en)
EA (1)	EA007254B1 (en)
HU (1)	HUP0400692A3 (en)
IL (1)	IL155962A0 (en)
ME (1)	MEP35308A (en)
MX (1)	MXPA03004717A (en)
NO (1)	NO327207B1 (en)
NZ (1)	NZ525885A (en)
OA (1)	OA13295A (en)
PL (1)	PL363245A1 (en)
WO (1)	WO2002057267A1 (en)
YU (1)	YU42703A (en)
ZA (1)	ZA200303729B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5090531A (en) *	1990-01-10	1992-02-25	Lord Corporation	Electrophoretic fluid differential
HUP0103836A3 (en)	1998-06-02	2003-05-28	Osi Pharmaceuticals Inc Uniond	Pyrrolo[2,3d]pyrimidine compositions and their use
US6680324B2 (en)	2000-12-01	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (en) *	2001-10-04	2003-04-10	Merck Patent Gmbh	New fused bi- or tricyclic pyrimidine derivatives, are phosphodiesterase V inhibitors useful e.g. for treating impotence, cardiovascular disorders, inflammation or tumors
JP2005529062A (en)	2001-11-30	2005-09-29	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	Compounds specific for adenosine A1 and A3 receptors and uses thereof
ATE466581T1 (en) *	2001-12-07	2010-05-15	Vertex Pharma	PYRIMIDINE-BASED COMPOUNDS AS GSK-3 INHIBITORS
DE60236458D1 (en)	2001-12-20	2010-07-01	Osi Pharm Inc	PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONISTIC COMPOUNDS, THEIR SYNTHESIS AND USE
KR20040068317A (en)	2001-12-20	2004-07-30	오에스아이 파마슈티컬스, 인코포레이티드	Pyrimidine a2b selective antagonist compounds, their synthesis and use
EP1556053A4 (en) *	2002-10-31	2006-04-19	Amgen Inc	Antiinflammation agents
HUP0203976A3 (en) *	2002-11-15	2004-08-30	Sanofi Aventis	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
UY29177A1 (en)	2004-10-25	2006-05-31	Astex Therapeutics Ltd	SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES
MY179032A (en)	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
DE602006013792D1 (en) *	2005-02-18	2010-06-02	Solvay Pharm Gmbh	PHARMACEUTICAL COMPOSITIONS WITH NEP INHIBITORS, INHIBITORS OF ENDOGENOUS ENDOTHELIN PRODUCING SYSTEM AND DIETETICS
WO2007125321A2 (en)	2006-04-25	2007-11-08	Astex Therapeutics Limited	Purine and deazapurine derivatives as pharmaceutical compounds
US20070260203A1 (en) *	2006-05-04	2007-11-08	Allergan, Inc.	Vasoactive agent intraocular implant
TW200808819A (en) *	2006-06-19	2008-02-16	Solvay Pharm Gmbh	Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
BRPI0818533B8 (en)	2007-10-11	2021-05-25	Astrazeneca Ab	compound, pharmaceutical composition, use of a compound, and, process for preparing a compound
AR070127A1 (en)	2008-01-11	2010-03-17	Novartis Ag	PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS
KR20100116607A (en)	2008-01-11	2010-11-01	낫코 파마 리미티드	Novel pyrazolo [3,4-d] pyrimidine dericatives as anti-cancer agents
ME03589B (en)	2011-04-01	2020-07-20	Astrazeneca Ab	THERAPEUTIC TREATMENT
MX367640B (en)	2011-11-30	2019-08-29	Astrazeneca Ab	Combination treatment of cancer.
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
BR112014030416A2 (en) *	2012-06-07	2017-06-27	Hoffmann La Roche	compound, methods for tankyrase 1 inhibition and cancer treatment, use of a compound, composition and invention.
CN105473581B (en) *	2013-06-21	2019-04-23	齐尼思表观遗传学有限公司	Newly substituted bicyclic compounds as bromodomain inhibitors
KR102307566B1 (en)	2013-06-21	2021-10-05	제니쓰 에피제네틱스 리미티드	Novel bicyclic bromodomain inhibitors
CA2919948C (en)	2013-07-31	2020-07-21	Zenith Epigenetics Corp.	Novel quinazolinones as bromodomain inhibitors
US10179125B2 (en)	2014-12-01	2019-01-15	Zenith Epigenetics Ltd.	Substituted pyridines as bromodomain inhibitors
HK1245246A1 (en)	2014-12-01	2018-08-24	恒翼生物医药科技(上海)有限公司	Substituted pyridinones as bromodomain inhibitors
WO2016092375A1 (en)	2014-12-11	2016-06-16	Zenith Epigenetics Corp.	Substituted heterocycles as bromodomain inhibitors
CN107406438B (en)	2014-12-17	2021-05-14	恒翼生物医药科技(上海)有限公司	Inhibitors of bromodomains
ES2962330T3 (en)	2015-01-20	2024-03-18	Wuxi Fortune Pharmaceutical Co Ltd	Jak inhibitor
EP3290418B1 (en)	2015-04-29	2019-05-15	Wuxi Fortune Pharmaceutical Co., Ltd	Janus kinase (jak) inhibitors
DK3305788T3 (en)	2015-05-29	2020-09-28	Wuxi Fortune Pharmaceutical Co Ltd	JANUS-KINASE-HIMMER
CN105771672B (en) *	2016-04-18	2018-03-02	天津工业大学	A kind of antipollution antibiotic aromatic polyamide reverse osmosis composite film and preparation method
CN108570054B (en) *	2017-03-07	2021-07-16	广州再极医药科技有限公司	Aminopyrimido five-membered heterocyclic compound, its intermediate, preparation method, pharmaceutical composition and application
CN108017584B (en) *	2017-06-20	2021-03-23	南开大学	A3Small molecule antagonists of adenosine receptors
WO2019233994A1 (en) *	2018-06-04	2019-12-12	Exscientia Ltd	Pyrazolopyrimidine compounds as adenosine receptor antagonists
CN110128316B (en) *	2019-05-22	2021-08-31	北京大学深圳研究生院	The preparation method of 5-substituted β-proline and its derivatives
CN110272373B (en) *	2019-07-02	2022-07-29	天津国际生物医药联合研究院	Selective adenosine A 1 Receptor antagonists and uses thereof
CN114085178A (en) *	2021-12-29	2022-02-25	苏州楚凯药业有限公司	Preparation method of 4-methyl-1-propyl-2-amino-1H-pyrrole-3-nitrile

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9307646A (en) *	1992-12-17	1999-05-25	Pfizer	Pyrrolopyrimidines as crf antagonists
US5780450A (en) *	1995-11-21	1998-07-14	Alcon Laboratories, Inc.	Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
HUP0103836A3 (en) *	1998-06-02	2003-05-28	Osi Pharmaceuticals Inc Uniond	Pyrrolo[2,3d]pyrimidine compositions and their use
ES2269217T3 (en) *	1999-12-02	2007-04-01	Osi Pharmaceuticals, Inc.	SPECIFIC COMPOUNDS FOR ADENOSINE A1, A2A AND A3 RECEPTORS AND THEIR USES.
JP2005529062A (en) *	2001-11-30	2005-09-29	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	Compounds specific for adenosine A1 and A3 receptors and uses thereof

2001
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/en not_active Application Discontinuation
- 2001-11-30 CN CNB018224601A patent/CN1263757C/en not_active Expired - Fee Related
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en not_active Ceased
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/en unknown
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 EA EA200300628A patent/EA007254B1/en not_active IP Right Cessation
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/en not_active Expired - Fee Related
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/en active IP Right Grant
- 2001-11-30 PL PL01363245A patent/PL363245A1/en not_active Application Discontinuation
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/en unknown
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/en unknown
- 2001-11-30 YU YU42703A patent/YU42703A/en unknown
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 IL IL15596201A patent/IL155962A0/en unknown
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
BR0115847A (en)	2004-02-25
OA13295A (en)	2007-04-13
MXPA03004717A (en)	2004-06-30
JP4579497B2 (en)	2010-11-10
AP2003002807A0 (en)	2003-06-30
EP1347980A1 (en)	2003-10-01
MEP35308A (en)	2011-02-10
NO20032482L (en)	2003-07-28
JP2004517896A (en)	2004-06-17
EA200300628A1 (en)	2003-12-25
YU42703A (en)	2006-03-03
NZ525885A (en)	2005-01-28
AP1893A (en)	2008-09-23
ZA200303729B (en)	2004-05-14
CZ20031831A3 (en)	2004-05-12
EP1347980A4 (en)	2005-02-09
CA2430577A1 (en)	2002-07-25
AU2002248151B2 (en)	2008-02-21
HUP0400692A2 (en)	2004-07-28
CN1489590A (en)	2004-04-14
WO2002057267A1 (en)	2002-07-25
IL155962A0 (en)	2003-12-23
NO20032482D0 (en)	2003-06-02
NO327207B1 (en)	2009-05-11
EA007254B1 (en)	2006-08-25
CN1263757C (en)	2006-07-12
HUP0400692A3 (en)	2007-09-28

Legal Events

Date	Code	Title	Description
2011-09-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
GB0022370D0 (en)	2000-10-25	Improvements to televisionn system
IL155962A0 (en)	2003-12-23	Compounds specific to adenosine a1, a2a, and a3 receptors and uses thereof
EP1287154A4 (en)	2010-12-15	Charge-switch nucleotides
GB0006513D0 (en)	2000-05-10	Improvements relating to converters
GB0006247D0 (en)	2000-05-03	Improvements in or relating to organic compounds
GB0021404D0 (en)	2000-10-18	Improvement in or to organic compounds
GB2360322B (en)	2003-08-06	Improvements relating to fasteners
GB2364338B (en)	2004-01-28	Improvements relating to construction
GB0025524D0 (en)	2000-11-29	Improvements relating to screenboxes
GB2363331B (en)	2003-02-05	Supplement to enhance fertility
GB0121137D0 (en)	2001-10-24	Improvements to motorbility vehicles
GB2388346B (en)	2004-01-21	Improvements relating to vehicles
GB0013038D0 (en)	2000-07-19	Improvements relating to bicycles
GB2359528B (en)	2004-01-21	Improvements relating to vehicles
GB0314796D0 (en)	2003-07-30	Improvements relating to thermometers
GB0017107D0 (en)	2000-08-30	Improvements to velodromes
GB0025715D0 (en)	2000-12-06	Improvements relating to haribrushes
HRPK20000423B1 (en)	2002-06-30	Novel nucleosides
GB0022811D0 (en)	2000-11-01	Improvements relating to supports
GB2345464B (en)	2001-06-27	Improvements relating to forms
GB0007565D0 (en)	2000-05-17	Improvements relating to radiators
GB0029608D0 (en)	2001-01-17	Improvements relating to lamp-holder
GB0008226D0 (en)	2000-05-24	Improvements relating to spanners
GB0026477D0 (en)	2000-12-13	Improvements relating to back supports
GB9905362D0 (en)	1999-05-05	Improvements related to demisting compounds